- Home
- TT vs REGN Comparison
TT vs REGN Comparison
Compare TT & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TT
- REGN
- Stock Information
- Founded
- TT 1885
- REGN 1988
- Country
- TT Ireland
- REGN United States
- Employees
- TT N/A
- REGN N/A
- Industry
- TT Auto Parts:O.E.M.
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- TT Industrials
- REGN Health Care
- Exchange
- TT Nasdaq
- REGN Nasdaq
- Market Cap
- TT 78.4B
- REGN 63.4B
- IPO Year
- TT N/A
- REGN 1991
- Fundamental
- Price
- TT $419.63
- REGN $508.90
- Analyst Decision
- TT Hold
- REGN Buy
- Analyst Count
- TT 15
- REGN 23
- Target Price
- TT $405.60
- REGN $854.26
- AVG Volume (30 Days)
- TT 1.1M
- REGN 1.5M
- Earning Date
- TT 07-30-2025
- REGN 07-31-2025
- Dividend Yield
- TT 0.90%
- REGN 0.35%
- EPS Growth
- TT 28.63
- REGN 16.49
- EPS
- TT 12.02
- REGN 39.43
- Revenue
- TT $20,311,200,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- TT $11.74
- REGN N/A
- Revenue Next Year
- TT $7.14
- REGN $6.83
- P/E Ratio
- TT $34.84
- REGN $12.92
- Revenue Growth
- TT 11.43
- REGN 7.52
- 52 Week Low
- TT $298.15
- REGN $476.49
- 52 Week High
- TT $436.61
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- TT 51.60
- REGN 41.90
- Support Level
- TT $418.49
- REGN $503.25
- Resistance Level
- TT $432.08
- REGN $538.20
- Average True Range (ATR)
- TT 6.73
- REGN 15.52
- MACD
- TT -3.35
- REGN 1.72
- Stochastic Oscillator
- TT 14.86
- REGN 58.56
About TT Trane Technologies plc
Trane Technologies manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its prominent Trane, American Standard, and Thermo King brands. The $20 billion company generates approximately 70% of sales from equipment and 30% from parts and services. While the firm is domiciled in Ireland, North America accounts for over 80% of its revenue.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).